CN105919096A - Healthcare food composition and preparation and application thereof - Google Patents
Healthcare food composition and preparation and application thereof Download PDFInfo
- Publication number
- CN105919096A CN105919096A CN201610318193.4A CN201610318193A CN105919096A CN 105919096 A CN105919096 A CN 105919096A CN 201610318193 A CN201610318193 A CN 201610318193A CN 105919096 A CN105919096 A CN 105919096A
- Authority
- CN
- China
- Prior art keywords
- group
- health
- food composition
- care food
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 235000013305 food Nutrition 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title abstract description 22
- 210000004369 blood Anatomy 0.000 claims abstract description 29
- 239000008280 blood Substances 0.000 claims abstract description 29
- 235000003935 Hippophae Nutrition 0.000 claims abstract description 19
- 241000229143 Hippophae Species 0.000 claims abstract description 19
- 239000009609 fructus phyllanthi Substances 0.000 claims abstract description 18
- 239000009636 Huang Qi Substances 0.000 claims abstract description 17
- 239000007788 liquid Substances 0.000 claims description 34
- 239000002775 capsule Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 10
- 230000003285 pharmacodynamic effect Effects 0.000 abstract description 2
- 235000014375 Curcuma Nutrition 0.000 abstract 1
- 244000164480 Curcuma aromatica Species 0.000 abstract 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- 239000000284 extract Substances 0.000 description 43
- 239000000243 solution Substances 0.000 description 32
- 238000012360 testing method Methods 0.000 description 26
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 21
- 238000000605 extraction Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 11
- 102000004877 Insulin Human genes 0.000 description 10
- 108090001061 Insulin Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 229940125396 insulin Drugs 0.000 description 10
- 239000002994 raw material Substances 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 5
- 210000004153 islets of langerhan Anatomy 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 240000005373 Panax quinquefolius Species 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010065952 Hyperpathia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000009146 rhinoscleroma Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical compound C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine or healthcare food and particularly relates to a healthcare food composition and a preparation and application thereof. The composition is prepared from fructus hippophae, folium mori, rhodiolae roots, radix astragali, radix curcuma and fructus phyllanthi. Pharmacodynamic study shows that the composition has very good effects of tonifying qi, decreasing blood sugar and the like.
Description
Technical field
The invention belongs to technical field of Chinese medicines or technical field of health care food, be specifically related to a kind of health food group
Compound and preparation thereof and purposes.
Background technology
Diabetes are a kind of whole body chronic progressive diseases.Due to islet cells can not normal secretions insulin, because of
And insulin is relatively or definitely not enough, and the reduction that target cell is to insulin sensitivity, and cause sugar, albumen,
Fat and water and electrolyte metabolism are disorderly, make hepatic glycogen and muscle glycogen not to synthesize.Clinical manifestation be blood glucose raise,
Glucose in urine is positive and carbohydrate tolerance reduces, and classical symptom is " three-many-one-little ", i.e. polydipsia, polyuria, polyphagia and body weight subtracts
Few；Diabetes are clinical common, multiple endocrine metabolism not normal property diseases, have difficult radical cure, complication many,
The feature that sickness rate, mortality rate, disability rate are high, serious threat human health.Hyperglycemia can jeopardize whole body of human body
Organ, causes human brain vascular atherosclerosis to cause hypertension, hyperlipidemia, severe patient generation myocardial infarction,
Cerebral infarction and cerebral hemorrhage；Also can cause renal failure because of three grades of vascular lesions of kidney, albuminuria occurs clinically；
Also can cause nervous system injury, hyperpathia or disappearance occur；Acra limitation of activity, myasthenia, constipation,
Sexual impotence, bone paresis；Can cause blurring of vision because of retinopathy, severe patient is blind；Hyperglycemia more can cause
Blood vessel and Small vessel cause the generation of diabetic foot, occur that foot ulcers, gangrene are even had to amputation.
Traditional Chinese medical science diabetes are called diabetes, and the classical medical book-Huangdi's Internal Classics of China is according to different pathogenesis, master
Card call respectively it " quench one's thirst ", " diseases due to endogenous heat of ZANG FU organs ", " diabetes involving in upper-JIAO ", " diabetes involving the upper-JIAO ", " in disappearing " etc., ancient medical book " dredge by origin of Chinese character disease
Under " explain: " and disappear, electricity to be drunk." " disease was waited and dredged justice ancient times " explanation: " ... body fluid is quenched one's thirst, therefore wishes to get water
Also." name for diabetes, polyuria is its feature: " its people one daily drink is a pipeful of, and urine is the most a pipeful of." Han dynasty
Zhang Zhongjing " gold plaque " is loaded with: " drinking a great quantity of water but thirst unrelieved, ", " thirst with desire to drink water, dry mouth and tougue.", add: " disappear
Paddy diet, stool must be hard, and urine must count.", Li Gao " secret record of the orchid chamber " says and quenches one's thirst: " dry mouth and tougue, urine
Frequency, stool closes puckery, is dried scleroma." to add " can eat and thin " these records similar to the symptom of diabetes.
Therefore ancient Chinese medicine doctor calls diabetes diabetes always.
Along with our people's growth in the living standard, the dietary structure of people there occurs great changes, the most not
Reasonably diet, makes internal insulin secrete for a long time more, gradually causes insulin target cell to insulin
Sensitivity reduce, thus create hyperglycemia, the sickness rate of diabetes improves the most therewith, at present, treatment
The medicine of diabetes mostly biases toward stimulation islets of langerhans and produces insulin, and the target cell of insulin is to insulin
Sensitivity does not obtain basic improvement, so once after drug withdrawal a period of time, blood glucose rebounds the most again,
Simultaneously as the stimulation that long-term prescription is to islets of langerhans, islets of langerhans is made to be in long-term nervous duty, and final
Cause the tired out of islet function, cause diabetes patient finally to have to by external islets of langerhans and usually help blood sugar lowering,
So can further result in the part or all of forfeiture of islet function, simultaneously because blood glucose rebounds repeatedly, still make
The viscosity of blood increases, and the microcirculation generation obstacle of blood the most still can occur the heart, brain, kidney and skin
The complication of the aspects such as nerve.
Research and develop a kind of new health food with hypoglycemic activity, for diabetics, tool
Significant.
Summary of the invention
For these reasons, applicant is through clinical research for many years, based on theory of Chinese medical science, in conjunction with modern
Medical research, invents a kind of new health-care food composition, and said composition raw material is: Fructus Hippophae, Folium Mori, red
Herba hylotelephii erythrosticti, the Radix Astragali, Rhizoma Curcumae Longae, Fructus Phyllanthi.Pharmacodynamic study shows, the present composition has well
Improve QI invigorating, blood sugar lowering etc. effect.
Fructus Hippophae and Folium Mori in formula, Papillary is monarch drug altogether；Radix Rhodiolae, the Radix Astragali are auxiliary for ministerial drug altogether after share
Help Fructus Hippophae and Folium Mori, to strengthen effect.Assistant is with Rhizoma Curcumae Longae, Fructus Phyllanthi.All tastes share, play altogether enhancing QI invigorating,
Effect of blood sugar lowering.
The present invention is achieved through the following technical solutions.
A kind of health-care food composition, said composition includes: Fructus Hippophae, Folium Mori, Radix Rhodiolae, the Radix Astragali,
Rhizoma Curcumae Longae, Fructus Phyllanthi.
Wherein: Fructus Hippophae 5-10 weight portion, Folium Mori 3-8 weight portion, Radix Rhodiolae 4-12 weight portion, yellow
Stilbene 3-5 weight portion, Rhizoma Curcumae Longae 1-5 weight portion, Fructus Phyllanthi 4-8 weight portion.
The application in blood sugar reducing food of the described a kind of health-care food composition.
The application in QI invigorating food of the described a kind of health-care food composition.
The oral formulations that compositions described above is prepared as.
Tablet that compositions described above is prepared as or capsule.
The oral liquid that compositions described above is prepared as.
Detailed description of the invention
Test example 1 toxicological test
Test group: Fructus Hippophae 80g, Folium Mori 60g, Radix Rhodiolae 80g, Radix Astragali 40g, Rhizoma Curcumae Longae 30g,
Fructus Phyllanthi 60g.
Preparation method: take above-mentioned raw materials, adding 3000ml concentration is 60% ethanol, extracts 2 hours, filters,
Obtaining extracting solution A, it is 45% ethanol that residue adds 2500ml concentration, extracts 2 hours, filters, is carried
Taking liquid B, residue adds 2000ml water, extracts 1.5 hours, filters, obtains extracting solution C, united extraction
Liquid A and extracting solution B, reclaims ethanol to the greatest extent, united extraction liquid C, and concentrate drying obtains extract.
1. mice LD50 measures
Take healthy mice 60, male and female half and half, body weight 18-22g, be randomly divided into 6 groups, often group 10.
Each group presses the dosage of 0.4g/kg, 0.8g/kg, 1.6g/kg, 3.2g/kg, 6.4g/kg, 12.8g/kg (respectively respectively
Be equivalent to adult 6.25 times of dosage, 12.5 times, 25 times, 50 times, 100 times, 200 times), preparation
Become respective concentration, be 0.25ml/10g by amount of liquid medicine every time, all animals gastric infusion once a day, even
Continuous 7 days.Observe during medication animal activity, diet, two just, hair color, figure etc. be showed no exception.7th
Animal is all put to death dissection by it, observes each important organ and organizes also no abnormality seen.This compositions pair is described
Mice LD50 is far longer than 12.8g/kg (being equivalent to 200 times of adult's dosage).
2. mice maximum tolerance determination
Take healthy mice 20, male and female half and half, body weight 18-22g.The extract this compositions obtained steams
After distilled water is dissolved, water-soluble to 50% concentration, by gastric infusion after whole mice fasting 12h, each 0.7ml,
Every day 2 times, continuous gavage 7 days.Observe animal activity, diet, two just etc. all normal, put to death dissect dynamic
Thing observes each important organ and tissue is the most no abnormal.Illustrate that the application granule is to mice maximum tolerated dose
For 36g/kg (being equivalent to 562.5 times of adult's dosage).
3. long term toxicity test
Take healthy rat 80, body weight 90-110g, male and female half and half, be randomly divided into four groups, i.e. compositions is extracted
Thing high, medium and low dosage group and Normal group, often group 20.Respectively group gavage respectively is with 3g/kg.1.5g/kg,
0.75g/kg this compositions extract suspension and etc. dosage normal saline. every time 3ml/100g, every day 1 time,
Within every 2 weeks, weighing 1 time, to adjust dosage, successive administration is after 12 weeks, at each treated animal 1-10 broken end
Extremely take hematometry routine blood test and liver function, kidney merit.Dissect after taking blood, perusal main organs form；Successively
Taking-up is weighed.Calculate and record dirty body ratio；Take out bladder, take urine from bladder and do routine urianlysis；Will be main
Internal organs are fixed by 10% formalin, and histological examination is done in section.Remain each group of 11-20 animal drug withdrawal to observe
After two weeks, same above-mentioned steps and method, obtain every test data.Result all animals blood, urine are often
Rule and Liver and kidney function all compare between normal range, group and there was no significant difference；Each main organs perusal
Form is without exception.Histological examination cellular prion protein is normal, changes without pathologic；Dirty body than each group without aobvious
Write sex differernce.
Conclusion (of pressure testing): the acute toxicity tests shows: mice LD50 is far longer than 12.8g/kg and (is equivalent to people use
200 times of amount), mice maximum tolerated dose reaches 36g/kg (being equivalent to 562.5 times of people's consumption).Long term toxicity tries
Test result prompting: to test rat serum is conventional and Liver and kidney function has no significant effect, to the test each internal organs of rat without
Infringement.Illustrate that this compositions is without obvious toxic-side effects.
Three. pharmacological testing
Test material
Experimental animal: Japanese purebred large ear rabbit, male and female half and half, female person without pregnant, body weight 2kg scholar 0.2kg；
Kunming mouse, male and female half and half, body weight 20g scholar 2g；SD rat, male and female half and half, body weight 100g scholar 10g.
Trial drug:
Test 1 group: Fructus Hippophae 50g, Folium Mori 30g, Radix Rhodiolae 40g, Radix Astragali 30g, Rhizoma Curcumae Longae 10g,
Fructus Phyllanthi 40g.
Test 2 groups: Fructus Hippophae 100g, Folium Mori 80g, Radix Rhodiolae 120g, Radix Astragali 50g, Rhizoma Curcumae Longae 50g,
Fructus Phyllanthi 80g.
Test 3 groups: Fructus Hippophae 80g, Folium Mori 60g, Radix Rhodiolae 80g, Radix Astragali 40g, Rhizoma Curcumae Longae 30g,
Fructus Phyllanthi 60g.
Test 1 group-test 3 groups of preparation methoies: taking above-mentioned raw materials, adding 3000ml concentration is 60% ethanol,
Extracting 2 hours, filter, obtain extracting solution A, it is 45% ethanol that residue adds 2500ml concentration, extracts 2
Hour, filtering, obtain extracting solution B, residue adds 2000ml water, extracts 1.5 hours, filters, obtains
Extracting solution C, united extraction liquid A and extracting solution B, recovery ethanol is to the greatest extent, and united extraction liquid C, concentration is dry
Dry, obtain extract.
Positive controls: commercially available Fructus Momordicae charantiae American ginseng soft capsule.
Main agents: alloxan, SIGMA chemical company of the U.S. produces；Adrenalin hydrochloride injection.
Every 1ml, containing 1mg；Blood sugar kit；Clear insulin radioimmunoassay medicine box.
Key instrument: 721 type spectrophotometers；Put and exempt from detector；Generic centrifuge, three with water temperature cases, from
Automatic Biochemical Analyzer.
Test 1
The impact that alloxan diabetes Rabbits ' Blood Sugar and serum insulin are discharged
Choosing healthy rabbits 68, body weight 1.85-2.15kg, male and female half and half, after fasting 12h, to wherein 60
Auricular vein injects 5% alloxan normal saline solution 120mg/kg, and another 8 (are just left intact
Often matched group).After modeling 64h, all animals fasting 12h again, rapid heart takes blood, uses ortho-aminotoluene method
Mensuration fasting blood is warded off.By 20 higher and relatively low for blood glucose in modeling rabbit rejectings, choose blood sugar level close
Hyperglycemia rabbit 40 (blood glucose value is 14.11-20.84mmol/L), be randomly divided into five groups, often group 8,
It is respectively model control group, positive controls and test group of the present invention.Normal group and model control group are used
Normal saline 5ml/kg；Positive test group 2.4g/kg；Test 1 group-test 3 groups to 1.5g/kg.All join
Make suspension.By the consumption of per kilogram of body weight 5ml, gastric infusion once a day, continuous surrounding.Filling
During medicine, all give normal diet, and note strengthening output.After being administered full surrounding, fasting 12h will be complete
Portion's animal hearts takes blood, measures rabbit fasting glucose (BG) and serum insulin (IRI) value.
The results are shown in Table 1.
Table 1 is to alloxan diabetes rabbit fasting glucose and the shadow noon of serum insulin levels
Note: * P ＜ 0.05**P ＜ 0.01 compared with model control group；△ P ＜ 0.05 compared with positive ball group.
From table 1, commercially available Fructus Momordicae charantiae American ginseng soft capsule and Ben Ming compositions are respectively organized all to have and are substantially reduced diabetes
The effect of Rabbits ' Blood Sugar level.Health-care food composition group of the present invention has than commercially available Fructus Momordicae charantiae American ginseng soft capsule group
Hypoglycemic effect is preferably dropped.
Test 2
Impact on adrenaline-induced hyperglycosemia rats blood sugar level
Take healthy mice 60, body weight 18-22g, male and female half and half, be randomly divided into 6 groups, often group 10,
It is respectively Normal group, model control group, commercially available health product group and health composition group of the present invention.Normally
Group and model group gavage respectively is with 0.25ml/10g normal saline.The commercially available commercially available health care of health product group 2.5g/kg
Product；Halth-care composition group dosage 1.5g/kg of the present invention.Above 4 groups are configured to the mixed of variable concentrations respectively
Suspension, all rolls over to obtain 0.25ml/10g volume.Each group gastric infusion the most once a day, continuous one week, in last
After being administered 1h, in addition to normal group, to remaining each treated animal equal lumbar injection epinephrine 0.2mg/kg, 30min
The rear equal eye socket of all animals takes blood, measures blood sugar concentration by ortho-aminotoluene method.
The results are shown in Table 2.
Table 2 is to adrenaline-induced hyperglycosemia rats blood sugar level shadow noon
| Group | N | Blood glucose value mmol/L (x scholar SD) |
| Normal group | 10 | 6.35±0.34** |
| Model control group | 10 | 13.72±0.46 |
| Positive test group | 10 | 10.72±0.58* |
| Test 1 group | 10 | 8.13±0.49*△ |
| Test 2 groups | 10 | 8.25 scholar 0.73* △ |
| Test 3 groups | 10 | 7.71 soil 0.62* △ |
Note: * P ＜ 0.05**P ＜ 0.01 compared with model control group；△ P ＜ 0.05 compared with positive ball group.
From table 2, Halth-care composition group of the present invention can make adrenaline-induced hyperglycosemia rats blood sugar level
Reducing, compared with commercially available Fructus Momordicae charantiae American ginseng soft capsule group, its blood sugar reducing function is more preferable.
Preparation embodiment
Embodiment 1
Health-care food composition: Fructus Hippophae 50g, Folium Mori 30g, Radix Rhodiolae 40g, Radix Astragali 30g, Rhizoma Curcumae Longae
10g, Fructus Phyllanthi 40g.
Preparation method: take above-mentioned raw materials, adding 3000ml concentration is 60% ethanol, extracts 2 hours, mistake
Filter, obtains extracting solution A, and it is 45% ethanol that residue adds 2500ml concentration, extracts 2 hours, filters,
Obtaining extracting solution B, residue adds 2000ml water, extracts 1.5 hours, filters, obtains extracting solution C, closes
And extracting solution A and extracting solution B, reclaim ethanol to the greatest extent, united extraction liquid C, concentrate drying, is extracted
Thing；
Obtain the extract customary preparation methods according to oral formulations, prepare tablet, capsule, granule
Agent or oral liquid etc..
Embodiment 2
Health-care food composition: Fructus Hippophae 100g, Folium Mori 80g, Radix Rhodiolae 120g, Radix Astragali 50g, Rhizoma Zingiberis Recens
Yellow 50g, Fructus Phyllanthi 80g.
Preparation method: take above-mentioned raw materials, adding 3000ml concentration is 60% ethanol, extracts 2 hours, filters,
Obtaining extracting solution A, it is 45% ethanol that residue adds 2500ml concentration, extracts 2 hours, filters, is carried
Taking liquid B, residue adds 2000ml water, extracts 1.5 hours, filters, obtains extracting solution C, united extraction
Liquid A and extracting solution B, reclaims ethanol to the greatest extent, united extraction liquid C, and concentrate drying obtains extract；
Obtain the extract customary preparation methods according to oral formulations, prepare tablet, capsule, granule
Agent or oral liquid etc..
Embodiment 3
Health-care food composition: Fructus Hippophae 80g, Folium Mori 60g, Radix Rhodiolae 80g, Radix Astragali 40g, Rhizoma Curcumae Longae
30g, Fructus Phyllanthi 60g.
Preparation method: take above-mentioned raw materials, adding 3000ml concentration is 60% ethanol, extracts 2 hours, filters,
Obtaining extracting solution A, it is 45% ethanol that residue adds 2500ml concentration, extracts 2 hours, filters, is carried
Taking liquid B, residue adds 2000ml water, extracts 1.5 hours, filters, obtains extracting solution C, united extraction
Liquid A and extracting solution B, reclaims ethanol to the greatest extent, united extraction liquid C, and concentrate drying obtains extract；
Obtain the extract customary preparation methods according to oral formulations, prepare tablet, capsule, granule
Agent or oral liquid etc..
Embodiment 4
Health-care food composition: Fructus Hippophae 55g, Folium Mori 35g, Radix Rhodiolae 45g, Radix Astragali 35g, Rhizoma Curcumae Longae
15g, Fructus Phyllanthi 45g.
Preparation method: take above-mentioned raw materials, adding 3000ml concentration is 60% ethanol, extracts 2 hours, filters,
Obtaining extracting solution A, it is 45% ethanol that residue adds 2500ml concentration, extracts 2 hours, filters, is carried
Taking liquid B, residue adds 2000ml water, extracts 1.5 hours, filters, obtains extracting solution C, united extraction
Liquid A and extracting solution B, reclaims ethanol to the greatest extent, united extraction liquid C, and concentrate drying obtains extract；
Obtain the extract customary preparation methods according to oral formulations, prepare tablet, capsule, granule
Agent or oral liquid etc..
Embodiment 5
Health-care food composition: Fructus Hippophae 95g, Folium Mori 75g, Radix Rhodiolae 110g, Radix Astragali 45g, Rhizoma Curcumae Longae
45g, Fructus Phyllanthi 75g.
Preparation method: take above-mentioned raw materials, adding 3000ml concentration is 60% ethanol, extracts 2 hours, filters,
Obtaining extracting solution A, it is 45% ethanol that residue adds 2500ml concentration, extracts 2 hours, filters, is carried
Taking liquid B, residue adds 2000ml water, extracts 1.5 hours, filters, obtains extracting solution C, united extraction
Liquid A and extracting solution B, reclaims ethanol to the greatest extent, united extraction liquid C, and concentrate drying obtains extract；
Obtain the extract customary preparation methods according to oral formulations, prepare tablet, capsule, granule
Agent or oral liquid etc..
Embodiment 6
Health-care food composition: Fructus Hippophae 75g, Folium Mori 55g, Radix Rhodiolae 70g, Radix Astragali 35g, Rhizoma Curcumae Longae
25g, Fructus Phyllanthi 55g.
Preparation method: take above-mentioned raw materials, adding 3000ml concentration is 60% ethanol, extracts 2 hours, filters,
Obtaining extracting solution A, it is 45% ethanol that residue adds 2500ml concentration, extracts 2 hours, filters, is carried
Taking liquid B, residue adds 2000ml water, extracts 1.5 hours, filters, obtains extracting solution C, united extraction
Liquid A and extracting solution B, reclaims ethanol to the greatest extent, united extraction liquid C, and concentrate drying obtains extract；
Obtain the extract customary preparation methods according to oral formulations, prepare tablet, capsule, granule
Agent or oral liquid etc..
Embodiment 7
Health-care food composition: Fructus Hippophae 85g, Folium Mori 65g, Radix Rhodiolae 85g, Radix Astragali 45g, Rhizoma Curcumae Longae
35g, Fructus Phyllanthi 65g.
Preparation method: take above-mentioned raw materials, adding 3000ml concentration is 60% ethanol, extracts 2 hours, filters,
Obtaining extracting solution A, it is 45% ethanol that residue adds 2500ml concentration, extracts 2 hours, filters, is carried
Taking liquid B, residue adds 2000ml water, extracts 1.5 hours, filters, obtains extracting solution C, united extraction
Liquid A and extracting solution B, reclaims ethanol to the greatest extent, united extraction liquid C, and concentrate drying obtains extract；
Obtain the extract customary preparation methods according to oral formulations, prepare tablet, capsule, granule
Agent or oral liquid etc..
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all at this
Within bright spirit and principle, any modification, equivalent substitution and improvement etc. made, should be included in this
Within bright protection domain.
Claims (7)
1. a health-care food composition, it is characterised in that said composition includes: Fructus Hippophae, Folium Mori,
Radix Rhodiolae, the Radix Astragali, Rhizoma Curcumae Longae, Fructus Phyllanthi.
A kind of health-care food composition the most according to claim 1, wherein: Fructus Hippophae 5-10
Weight portion, Folium Mori 3-8 weight portion, Radix Rhodiolae 4-12 weight portion, Radix Astragali 3-5 weight portion, Rhizoma Curcumae Longae
1-5 weight portion, Fructus Phyllanthi 4-8 weight portion.
A kind of health-care food composition the most according to claim 1 and 2 is in blood sugar reducing food
Application.
A kind of health-care food composition the most according to claim 1 and 2 is in QI invigorating food
Application.
A kind of health-care food composition the most according to claim 1 and 2, it is characterised in that group
The oral formulations that compound is prepared as.
A kind of health-care food composition the most according to claim 1 and 2, it is characterised in that group
Tablet that compound is prepared as or capsule.
A kind of health-care food composition the most according to claim 1 and 2, it is characterised in that group
The oral liquid that compound is prepared as.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610318193.4A CN105919096B (en) | 2016-05-16 | 2016-05-16 | Health food composition, preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610318193.4A CN105919096B (en) | 2016-05-16 | 2016-05-16 | Health food composition, preparation and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105919096A true CN105919096A (en) | 2016-09-07 |
| CN105919096B CN105919096B (en) | 2020-05-22 |
Family
ID=56834960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610318193.4A Expired - Fee Related CN105919096B (en) | 2016-05-16 | 2016-05-16 | Health food composition, preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105919096B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110368391A (en) * | 2019-06-21 | 2019-10-25 | 中国科学院西北高原生物研究所 | Triterpenoid is preparing the purposes in hypoglycemic Related product |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1799582A (en) * | 2005-10-12 | 2006-07-12 | 牛西午 | Blood sugar- and blood pressure-lowering medicine |
| CN101711798A (en) * | 2009-12-18 | 2010-05-26 | 威海博力生物工程有限公司 | Preparation used for lowering blood fat and lowering blood sugar |
| CN103584102A (en) * | 2013-11-20 | 2014-02-19 | 山西振东五和健康食品股份有限公司 | Health food with auxiliary effect in lowering blood sugar and preparation method of health food |
| CN103608024A (en) * | 2011-04-01 | 2014-02-26 | 桂林商源植物制品有限公司 | Pharmaceutical composition for controlling blood sugar, blood lipid and body weight |
| CN104225456A (en) * | 2014-04-29 | 2014-12-24 | 遵义陆圣康源科技开发有限责任公司 | Pharmaceutical composition for reducing blood sugar |
| CN104606451A (en) * | 2014-12-30 | 2015-05-13 | 北京宝得瑞食品有限公司 | Medicine-food dual-purpose composition for reducing postprandial blood sugar (IGT state) and preparation method |
| CN105211849A (en) * | 2015-08-24 | 2016-01-06 | 吴峒何 | A kind of health food of prevention and therapy diabetes |
| CN105596735A (en) * | 2016-03-23 | 2016-05-25 | 陈佳宽 | Medicine composition for treating diabetes mellitus |
-
2016
- 2016-05-16 CN CN201610318193.4A patent/CN105919096B/en not_active Expired - Fee Related
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1799582A (en) * | 2005-10-12 | 2006-07-12 | 牛西午 | Blood sugar- and blood pressure-lowering medicine |
| CN101711798A (en) * | 2009-12-18 | 2010-05-26 | 威海博力生物工程有限公司 | Preparation used for lowering blood fat and lowering blood sugar |
| CN103608024A (en) * | 2011-04-01 | 2014-02-26 | 桂林商源植物制品有限公司 | Pharmaceutical composition for controlling blood sugar, blood lipid and body weight |
| CN103584102A (en) * | 2013-11-20 | 2014-02-19 | 山西振东五和健康食品股份有限公司 | Health food with auxiliary effect in lowering blood sugar and preparation method of health food |
| CN104225456A (en) * | 2014-04-29 | 2014-12-24 | 遵义陆圣康源科技开发有限责任公司 | Pharmaceutical composition for reducing blood sugar |
| CN104606451A (en) * | 2014-12-30 | 2015-05-13 | 北京宝得瑞食品有限公司 | Medicine-food dual-purpose composition for reducing postprandial blood sugar (IGT state) and preparation method |
| CN105211849A (en) * | 2015-08-24 | 2016-01-06 | 吴峒何 | A kind of health food of prevention and therapy diabetes |
| CN105596735A (en) * | 2016-03-23 | 2016-05-25 | 陈佳宽 | Medicine composition for treating diabetes mellitus |
Non-Patent Citations (3)
| Title |
|---|
| 凌关庭: "《保健食品原料手册（第二版）》", 31 May 2007, 化学工业出版社 * |
| 王振富等: "姜黄素对大鼠糖尿病防治作用的实验研究", 《中国应用生理学杂志》 * |
| 郭志英等: "余甘子治疗糖尿病及其并发症的研究进展", 《海峡药学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110368391A (en) * | 2019-06-21 | 2019-10-25 | 中国科学院西北高原生物研究所 | Triterpenoid is preparing the purposes in hypoglycemic Related product |
| CN110368391B (en) * | 2019-06-21 | 2022-11-08 | 中国科学院西北高原生物研究所 | Application of triterpene compound in preparation of products related to blood sugar reduction |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105919096B (en) | 2020-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN1327876C (en) | Chinese drugs compositions for treating diabetes and its complications | |
| CN100496570C (en) | Medicine preparation for reducing blood sugar and its preparation method | |
| CN103223111B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN102205095A (en) | Medicinal composition with auxiliary blood sugar reducing effect | |
| CN1299742C (en) | Medicine for treating diabetes, and its prepn. method | |
| CN103933346B (en) | A kind of compound for reducing blood suger and preparation method thereof | |
| CN102988905B (en) | Traditional Chinese medicine preparation for treating epilepsia and preparation method thereof | |
| CN102631526B (en) | Chinese medicinal composition for treating diabetes mellitus | |
| CN104083640B (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN106176773A (en) | Berberine hydrochloride and stachyose composition compositions and application | |
| CN101780227B (en) | Traditional Chinese medicine composition for treating acute stroke and preparation method thereof | |
| CN101647951A (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN103550281A (en) | Medicine composition for preventing and treating diabetes and diabetes complications and preparation thereof | |
| CN100423754C (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN105919096A (en) | Healthcare food composition and preparation and application thereof | |
| CN109010579A (en) | A kind of antioxidant and anti-aging Chinese traditional compound medicine and preparation method thereof | |
| CN102858359B (en) | Medicinal composition comprising alcohol-soluble and water-insoluble licorice extract, pharmaceutical preparation, pharmaceutical application, therapeutic method, and preparative method thereof | |
| CN108465061A (en) | It is a kind of to be used to treat pharmaceutical composition of Facial Recurrent Dermatitis and its preparation method and application | |
| CN108404088B (en) | Traditional Chinese medicine for treating type II diabetes and preparation method thereof | |
| CN103520684B (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN106109767A (en) | A kind of compound preparation preventing and treating non-alcohol fatty liver | |
| CN104352748A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN101406576B (en) | Chinese medicine for treating diabetes and preparation method | |
| CN104815140A (en) | Composition for preventing or/and treating diabetes and preparation method of composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 208, 2nd Floor, Yiming Xiya Biomedical Technology Co., Ltd., Lin Qionggang, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, 850000 Applicant after: Tibet Hai Rong Tang Guo Health Industry Co., Ltd. Address before: Room 208, 2nd Floor, Yiming Xiya Biomedical Technology Co., Ltd., Lin Qionggang, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, 850000 Applicant before: TIBET KANGDE BIOTECHNOLOGY CO., LTD. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200522 Termination date: 20210516 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |